XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
Revenue from collaborative arrangements and other contracts $ 0 $ 114,943
Operating expenses:    
Research and development 20,913,790 30,176,511
General and administrative 10,571,179 13,890,610
Total operating expenses 31,484,969 44,067,121
Loss from operations (31,484,969) (43,952,178)
Other income (expense):    
Interest income 1,500,290 2,207,171
Interest expense (177,833) (313,488)
(Loss) gain on investment in affiliated entity (126,018) 616,639
Net unrealized gain on available-for-sale equity securities 500,877 3,218,215
Other expense, net (682,218) (2,425,676)
Net loss $ (30,469,871) $ (40,649,317)
Net loss per share    
Basic (in dollars per share) [1] $ (1.31) $ (1.89)
Diluted (in dollars per share) [1] $ (1.31) $ (1.89)
Weighted average number of common shares outstanding    
Basic (in shares) [1] 23,291,512 21,536,476
Diluted (in shares) [1] 23,291,512 21,536,476
[1] Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.